In 2019, she said, she's anticipating a return to the basic biotech-business model.
Over the past five years, the Nasdaq biotech index is up 25%, though recently stocks have taken a tumble, putting them into correction territory, a term that refers to a 10% or greater decline from a stock's most recent peak. 'I'm enthused by the correction,' Samuels told Business Insider. Venrock partner Camille Samuels is ready to get back to the basics in biotech. Account icon An icon in the shape of a person's head and shoulders.
